RxDoctor Payments Data

Hannah Spears, PA

Physician Assistant · Dallas, TXNPI 1114431335

Payments from drug & device makers

$930in general payments, 2019–2025

Across 44 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$178
  • Novartis$144
  • Boehringer Ingelheim$129
  • Alnylam Pharmaceuticals Inc.$123
  • Pfizer$110
  • AstraZeneca$76
  • plus $169 from 6 others

What the payments were for

  • Food & beverage$91699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$18,933
Medicare patients
81
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan189$221,878
JardianceEmpagliflozin107$129,836
EliquisApixaban57$57,762
FarxigaDapagliflozin Propanediol17$24,662
XareltoRivaroxaban24$23,728
Metoprolol Succinate169$3,049
Potassium Chloride57$2,028
Carvedilol180$1,728
Bumetanide26$1,722
Eplerenone30$1,304
Torsemide33$994
Candesartan Cilexetil23$953
Digoxin50$837
Rosuvastatin Calcium44$645
Spironolactone137$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$144$221,878189 claims
Boehringer IngelheimJardiance$129$129,836107 claims
PfizerEliquis$110$57,76257 claims
AstraZenecaFarxiga$76$24,66217 claims
Johnson & JohnsonXarelto$55$23,72824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →